Bactiguard Holding AB’s Annual Report 2022

The annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from April 20 and can be ordered by sending an email to: info@bactiguard.com

This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 19.00 CEST on April 5, 2023.

For more information, please contact:
Carin Jakobson, CFO, mobile: +46 709 651 665
Bactiguard press office +46 8 440 58 80 info@bactiguard.com

About Bactiguard

Bactiguard is a global medtech company with a purpose to prevent infections. We provide safe, cost-effective, and easy-to-use infection prevention technology and solutions across five therapeutic areas – orthopedics, urology, intravascular/critical care, dental, and wound care.

Bactiguard’s unique technology is based on a thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard’s solutions are biocompatible and make a positive impact by decreasing patient suffering, saving lives and healthcare resources. The solutions also fight antimicrobial resistance, one of the most serious threats to global health and modern medicine.

Bactiguard operates through license partnerships with leading global medtech companies, such as BD and Zimmer Biomet, differentiating their medical devices with our coating technology, and through the Bactiguard Infection Protection (BIP) product portfolio. BIP includes coated medical devices such as catheters and trauma implants, and wound care products and sutures.

Bactiguard is headquartered in Stockholm, has production in Sweden and Malaysia, and in total around 210 employees. Listed on Nasdaq Stockholm, the company reported revenues of 253.5 MSEK in 2022.

Read more on www.bactiguard.com

Follow Bactiguard on LinkedIn